Clinical Trials Links:
Practice Information:
The following trials are open to patients with newly diagnosed and
recurrent glioblastoma:
Recurrent Glioblastoma
Compassionate Use Trial of Temodol in Recurrent Malignant Glioma.
Eligibility: Recurrent Malignant Glioma.
Protocol: Temodal, an oral agent, is taken five days out of each 4 week period.
Newly Diagnosed Glioblastoma
Phase II study of High-Dose Carboplatin Prior to Radiation Therapy
Eligibility: Newly diagnosed anaplastic astrocytoma, glioblastoma multiforme
Protocol: up to four cycles of Carboplatin are given prior to the administration of local field
radiation therapy. Follow-up chemotherapy is then given.
Newly Diagnosed Glioblastoma
Phase II study of RSR-13 plus Radiation Therapy in Newly Diagnosed Glioblastoma
Eligibility: Newly diagnosed glioblastoma multiforme
Protocol: All patients will undergo radiation therapy in combination with infusions of RSR-13 (an oxygen carrying substance believed to enhance the effect of radiation therapy on brain tumors) on each day of treatment.
Recurrent Glioblastoma
Phase I/II dose escalation study of Carboplatin and Thalidomide in recurrent high grade glioma
Eligibility: Recurrent high grade glial neoplasm, no prior carboplatin or cisplatinum based chemotherapy.
Protocol: Carboplatin is administered monthly and Thalidomide is administered daily. Up to six courses of therapy may be given.
Newly Diagnosed or Recurrent Glioblastoma
Phase II study of high-dose Carboplatin/Thiotepa with autologous stem-cell support in newly diagnosed or recurrent high grade glioma
Eligibility: Newly diagnosed or recurrent high grade glial neoplasm, No prior Thiotepa, Carboplatin, or Cisplatinum based chemotherapy.
Protocol: Following stem-cell harvest, high-dose Carboplatin and Thiotepa are administered followed by stem cell re-infusion. Two cycles of therapy are given.
Recurrent Glioblastoma
Phase II study of high-dose Cyclophosphamide/Etoposide with gCSF support in recurrent high grade glioma
Eligibility: Recurrent high grade glial neoplasm, No prior Cyclophosphamide or Etoposide, and failure of radiation therapy and carboplatin-based chemotherapy.
Protocol: high-dose Cyclophosphamide and Etoposide are followed by gCSF support. Treatment is repeated as tolerated.